The two-day ASCO Direct™ GU will take place again in Den Dolder. The ASCO Genitourinary Cancers Symposium brings this proven concept to the Netherlands for two days of knowledge sharing and multidisciplinary discussion.
Together, you will participate in selected sessions of ASCO GU, which will be presented and commented on by the scientific committee. In addition, there is a direct connection to San Francisco, the clinical significance in terms of Dutch practice is clarified, and there is time for discussion with colleagues.
ASCO Direct™ GU is managed by the Program Committee.
Program Committee
- Dr. André Bergman, internal medicine oncologist, NKI-AVL, Amsterdam
- Prof. Dr. Joost Boormans, urologist, Erasmus MC, Rotterdam
- Dr. Franchette van den Berkmortel, internal medicine oncologist, Zuyderland Hospital, Geleen-Heerlen
- Dr. Niven Mehra, Internal Medicine Oncologist, Radboud University Medical Center, Nijmegen
- Dr. Daniela Oprea-Lager, nuclear medicine physician, Radboud University Medical Center Nijmegen
- Dr. Jorg Oddens, urologist, Amsterdam UMC, location AMC, Amsterdam
- Dr. Floris Pos, radiation therapist, NKI-AVL, Amsterdam
- Dr. Rik Somford, urologist, Canisius-Wilhelmina Hospital, Nijmegen
Date and place
Friday, February 14 at 3:30 p.m. – Saturday, February 15, 2025 at 3:00 p.m.
Location: Ernst Sillem Hoeve Soestdijkerweg 10b, 3734 MH, Den Dolder.
Do you travel by public transport? Buses are available from Den Dolder station.
To whom?
Internal medicine oncologists, urologists, radiation therapists and isotope medicine doctors.
Accreditation
Accreditation is requested from NIV, NVU, NVRO, NVNG and VSR.
Costs
Participation including overnight stay €150.00 (incl. VAT).
Blocked?
If you unexpectedly cannot make it, please let us know by email. If you cancel on 14.1. until, you only pay administration costs of €35. Unfortunately we cannot refund if you cancel after January 14th. However, someone else can participate instead of you.
Investment
Attention: there is a limited number of places available for residents and nurses. The organization reserves the right to give priority to specialist doctors over doctors in training or those interested in another position.
Contact us
Springer Healthcare
Phone: 030 638 36 38
E: [email protected]
ASCO Direct™ GU 2025 is possible:
-
ASCO Direct Disclaimer
(The selection of abstracts included here was made by the program committee ASCO Direct™ 2025.)
The American Society of Clinical Oncology (ASCO®) was not involved in the selection of materials. This selection of abstracts does not necessarily represent a balanced view or a complete discussion of a particular topic. The thoughts and opinions expressed here do not necessarily reflect the ideas and opinions of ASCO. ASCO is not responsible for errors or omissions in translations. Mentioning a company, product, service or therapy should not be interpreted as a recommendation. It is the responsibility of the attending physician or other health care provider to determine the drug doses and the best treatment for the patient, relying on the patient’s independent experience and knowledge. Readers are advised to check the appropriate medical literature and product information currently provided by the manufacturer of each drug being administered to confirm dosage, method and time of administration or contraindications. Readers are also encouraged to contact the manufacturer if they have any questions about the product’s features or limitations.
© 2024 American Society of Clinical Oncology. ASCO Direct™ is an officially licensed program of the American Society of Clinical Oncology®. ASCO® is a registered trademark of the American Society of Clinical Oncology. All rights reserved.
This content is provided for educational and informational purposes only and for personal use only. Unauthorized copying is prohibited.
-
Privacy Policy
Within the framework of the GDPR, Springer complies with the laws and regulations in accordance with this law. The applicable privacy policy can be found here: Springer Healthcare.